Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2016 Earnings Presentation
20 slides from Bactiguard Holding Ab's earnings presentation, May 12, 2016
Slide 1: At war against infections
1 At war against infections Q1 presentation May 12, 2016
Slide 2: How to fight multi-resistance, the CDC perspective
2 How to fight multi-resistance, the CDC perspective
Slide 3: New Swedish strategy to fight antibiotic resistance
3 New Swedish strategy to fight antibiotic resistance Foto Kristian Pohl. Regeringskansliet In April the Swedish government presented a new strategy to combat antibiotic resistance, where prevention is at the top of the agenda. Antibiotic resistance is a major and growing threat to public health, th
Slide 4: Key Priorities 2016
4 Key Priorities 2016 Drive sales of our own Bactiguard Infection Prevention product portfolio Develop new license businesses Secure long-term refinancing
Slide 5: Highlights in Q1 2016
5 Highlights in Q1 2016 Major increase in sales of BIP portfolio 100 000 unit order from China Repeat business expanding Tender won in Sweden Adjustment affected revenue from C.R. Bard, back to normal levels in March Expanding clinical evidence Focus on developing license business Inau
Slide 6: Market Update
6 Market Update Focus on select markets and expanding the business SWEDEN • Breakthrough in tender • Increasing interest in CVC • Establishing reference sites CHINA MEA • First delivery made • Focus on volume markets • Marketing and training • Repeat business, big tenders activities initiated • Chal
Slide 7: Focus on China and India
7 Focus on China and India China • First order for 100 000 catheters • Deliveries started in Q1 2016 • Bulk of the order to be shipped in Q2 • Biggest launch in Bactiguard’s history • Sales reps and product specialist to be trained India • Majority of first order delivered in Q1 • Two major congress
Slide 8: Licensing business update
8 Licensing business update C.R. Bard • Successful partnership since 1995 • More than 150 million catheters sold to date • Generating stable annual revenues Vigilenz Medical Devices Sucessful partnership • Bactiguard coated orthopaedic implants since 1995 • Covering the Asean-markets • Certification
Slide 9: Expanding clinical trials and evidence
9 Expanding clinical trials and evidence • Indian post approval clinical study for urinary catheters initatied at all six sites • Clinical trial for new patient group with spinal cord injuries, who require chronic catheterisation and suffer from recurring infections. • Laboratory study indicates tha
Slide 10: Highlights
Financial highlights Financial overview 10 Highlights First quarter (Jan-Mar 2016) • Revenues of MSEK 26 (29), minus 10% compared to Q1 2015 (lower deliveries to C.R. Bard) • EBITDA of MSEK -1.6 (0.2)
Slide 11: Supplied products
Delivered products Financial overview 11 Supplied products • 87 600 BIP products delivered in Q1 2016 compared to approx. 4 700 during Q1 2015 • For the full year 2015 , 152 000 BIP products were delivered
Slide 12: Revenue streams
12 Revenue streams Two revenue streams in the income statement License BIP portfolio Bard (sales since 1995) and BIP Foley BIP ETT BIP CVC Vigilenz license deals 1 2 License BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfolio, acknowledged in t
Slide 13: Income distribution
Income distribution Financial overview 13 Income distribution Jan-Mar Jan-Mar Full year Full year MSEK 2016 2015 2015 2014 License revenues 22,8 26,8 125,3 89,8 Sales of BIP products 2,9 0,2 6,1 3,7 Other revenue 0,4 1,9 7,0 4,8 Total Revenues 26,0 29,0 138,5 98,3
Slide 14: License revenues from C.R. Bard
License revenues from C.R. Bard Financial overview 14 License revenues (SEKm) Q1 Q2 H1 Q3 Q4 Full year 2013 21,6 19,3 40,9 21,3 20,5 82,7 2014 22,5 22,8 45,3 24,3 20,2 89,8 2015 26,8 25,8 52,6 56,8 15,9 125,3 2016 22,8 Of which: - Adj additional order, MSEK -2.6 - Currency effect, MSEK -1.4 • MSEK 8
Slide 15: Key figures
Key figures Financial overview 15 Key figures Jan-Mar Jan-Mar Full year Key figures • EBITDA (Q1) MSEK -1.6 (0,2) 2016 2015 2015 Revenues, SEKm 26,0 29,0 138,5 EBITDA, SEKm -1,6 0,2 20,2 • Adjusted EBITDA , MSEK EBITDA margin, % -6% 1% 15% EBITDA1, SEKm -1,4 5,5 31,4 -1.4 (5.5) 1 EBITDA margin , % -
Slide 16: Financial flexibility and strength
Financial flexibility and strength Financial overview 16 • Equity ratio of 61 % • Net debt of MSEK 117,4 • Cash position of MSEK 24 • Nominal value outstanding bond MSEK 138 • Annual interest costs on bond going forward until maturity, MSEK 15.2 • The credit facility of 130 MSEK in total, combined w
Slide 17: Financial targets
17 Financial targets • Average sales growth of 20% per annum for a 5-year period, with 2015 (adjusted for the additional order from C.R. Bard) as the base year – starting point SEK 118.5 million • EBITDA margin of at least 30% at the end of the 5-year period • Equity ratio of at least 30% • Over tim
Slide 18: Concluding remarks
18 Concluding remarks • Well positioned for growth given increasing attention to antibiotic resistance and infection prevention • Major increase in sales of BIP portfolio, well under way towards at least doubling 2015 volume • First order and delivery to China • Repeat business expanding • Tender wo
Slide 19: More information is available at www.bactiguard.se
19 More information is available at www.bactiguard.se For questions and additional information, please contact: Christian Kinch, CEO: +46 8 440 58 80 christian.kinch@bactiguard.se Fredrik Järrsten, CFO: +46 725 500 089 fredrik.jarrsten@bactiguard.se Cecilia Edström, Vice President - Director of Sale
Slide 20: Questions
20 Bactiguard Fighting war against superbugs Questions